List view / Grid view
New studies show rates of blood clots were similar following vaccination with Vaxzevria and Comirnaty®, plus rates of rare blood clots are lower after the second Vaxzevria dose.
In its May meeting, the EMA’s drug safety committee (PRAC) concluded two safety signal reviews for COVID-19 vaccines and began several more.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
The US FDA has granted avatrombopag (Doptelet) ODD as around 10 percent of US cancer patients per year experience chemotherapy-induced thrombocytopenia (CIT) with no available treatment.
The FDA has approved Doptelet tablets to treat low blood platelet count in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure...
